Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

BACKGROUND: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations between human epidermal growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchini, Giampaolo, Kiermaier, Astrid, Bianchi, Giulia Valeria, Im, Young-Hyuck, Pienkowski, Tadeusz, Liu, Mei-Ching, Tseng, Ling-Ming, Dowsett, Mitch, Zabaglo, Lila, Kirk, Sarah, Szado, Tania, Eng-Wong, Jennifer, Amler, Lukas C., Valagussa, Pinuccia, Gianni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299741/
https://www.ncbi.nlm.nih.gov/pubmed/28183321
http://dx.doi.org/10.1186/s13058-017-0806-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299741/
https://www.ncbi.nlm.nih.gov/pubmed/28183321
http://dx.doi.org/10.1186/s13058-017-0806-9

Ejemplares similares